This would be the fourth authorized indication for luspatercept in the European Union. HSCT with a matched unrelated or haploidentical donor was a promising alternative in patients with severe aplastic anemia. Hydroxyurea therapy reduced blood transfusion by 75% among pediatric patients in sub-Saharan Africa with sickle cell anemia. Low hemoglobin and anemia were found to be modifiable risk factors associated with low cognitive function in older patients. C1-inhibitor administration during transfusions did not significantly suppress hemolysis in autoimmune hemolytic anemia. Iron deficiency anemia was associated with subsequent diagnosis of gastrointestinal cancers, particularly colorectal cancer. Letermovir reduced the rate of CMV infection within the first 100 days of transplant. Hypoxia-inducible factor-prolyl hydroxylase domain inhibitors may be a safer and more effective alternative to ESAs. IL-1β inhibition via canakinumab appears feasible as treatment for patients with concurrent anemia and clonal hematopoiesis. Danicopan added to C5 inhibitor therapy led to significantly improved hemoglobin concentrations in patients with PNH. Dr. Masarova spoke with HemeToday on findings from a treatment comparison of pacritinib and momelotinib in myelofibrosis. Testosterone replacement therapy improved anemia remission and new anemia prevention versus placebo in men with hypogonadism. A study indicates that blood transfusions for anemic patients hospitalized with heart attack may improve patient outcomes. Fostamatinib improved hemoglobin response in warm antibody autoimmune hemolytic anemia versus placebo in the FORWARD trial. Plasma thrombopoietin was significantly higher in aplastic anemia and myelodysplastic syndromes compared with control values. HSCT from a haploidentical donor and PTCy improved neutrophil and platelet engraftment compared with UCBT in aplastic anemia. Take a look at these important studies relevant to anemia, venous thromboembolism, sickle cell disease, and PNH. Anemia appeared to increase risk of dementia and cognitive decline, and concurrent high CRP levels may further increase risk. Anemia patients with nonvalvular atrial fibrillation have a higher risk of dying, a study finds. Preoperative anemia increases the risk of postoperative complications by over 30%.